Edition:
India

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

4.93USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$4.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,576
52-wk High
$11.24
52-wk Low
$4.30

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg

* PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis

* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING

27 Mar 2018

BRIEF-Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05

* CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D

* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D

16 Jan 2018

BRIEF-Redhill Biopharma Initiates Phase IIa Study With Abc294640(Yeliva) For Cholangiocarcinoma

* REDHILL BIOPHARMA ANNOUNCES INITIATION OF PHASE IIA STUDY WITH ABC294640 (YELIVA®) FOR CHOLANGIOCARCINOMA AT MAYO CLINIC AND MD ANDERSON Source text for Eikon: Further company coverage:

22 Dec 2017

BRIEF-Redhill Biopharma provides 2017 year-end business update

* REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​

05 Dec 2017

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

* Redhill Biopharma reports 2017 third quarter financial results

13 Nov 2017

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn's disease

09 Nov 2017

BRIEF-RedHill Biopharma prices public offering of its American Depositary Shares

* RedHill Biopharma prices public offering of its American Depositary Shares

08 Nov 2017

BRIEF-Redhill Biopharma announces proposed public offering of its American Depositary Shares

* Redhill Biopharma announces proposed public offering of its american depositary shares Source text for Eikon: Further company coverage:

08 Nov 2017

Earnings vs. Estimates

No consensus analysis data available.